On August 11, 2026 Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, reported financial results for the second quarter ended June 30, 2026 and provided a business update, including strategic leadership transitions marking the company’s next era of execution and growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ryan Cohlhepp, Pharm.D., Bicara’s President and Chief Operating Officer (COO) will succeed Claire Mazumdar, Ph.D., MBA as Chief Executive Officer (CEO) effective January 1, 2027. As part of this planned evolution in leadership, Dr. Mazumdar will serve as Vice Chair of the Board of Directors and Strategic Advisor, with the goal of ensuring a seamless transition as Bicara enters its next era of execution and growth. Dr. Mazumdar will leverage her deep institutional knowledge to provide management guidance and support future growth, while empowering the next phase of strategic and operational leadership at Dr. Cohlhepp’s direction as the company prepares for the potential commercialization of ficerafusp alfa in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), with topline data from an interim analysis of the FORTIFI-HN01 pivotal trial expected in mid-2027.

Tanya Green, Chief Development Officer, will succeed Dr. Cohlhepp as COO, effective January 1, 2027. Since joining Bicara in October 2025, Ms. Green has demonstrated enterprise-wide responsibility for driving operational strategy, execution, and organizational performance across key development and operational functions including global clinical operations, technical operations, regulatory affairs, quality, and program management.

Jenn Larson, CPA, has been appointed Chief Financial Officer and will succeed Ivan Hyep, MBA, effective August 12, 2026. Ms. Larson is a tenured financial operator who brings decades of experience in roles of increasing strategic and operational responsibility at publicly traded, revenue-generating, commercial-stage biotechnology organizations.

Jenna Cohen will be promoted from Chief Corporate Affairs Officer to Chief Business Officer, effective January 1, 2027. Ms. Cohen has demonstrated an increasing scope of strategic and executional impact since joining Bicara in October 2025, and in her new role will retain oversight of corporate affairs, corporate development, and strategy.

Greg Shiferman, J.D., has been appointed Chief Legal Officer effective August 31, 2026. Mr. Shiferman is an accomplished life sciences professional who has served in executive positions across legal and program leadership. Mr. Shiferman brings deep experience providing strategic counsel across corporate development, commercialization, and governance. He will lead all aspects of our legal and compliance functions through key corporate milestones, including the potential commercial launch of ficerafusp alfa.
"This transition marks a natural evolution for Bicara as we maintain strong enrollment momentum that enables a clear line of sight to a topline interim analysis which we believe will lead to an accelerated approval and subsequent launch of ficerafusp alfa in head and neck cancer. I am incredibly proud of what our team has accomplished so far—transforming bold science into meaningful impact for patients while establishing a strong foundation for future growth. Having worked closely with Ryan since Bicara’s earliest days, I have seen firsthand his ability to translate strategy into disciplined execution, and we have been true partners in shaping the Bicara of today. I have complete confidence that he is the right leader to guide our next chapter," said Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics. "In addition, I want to thank Ivan for serving as an early executive at Bicara, for leading us through private and public offerings during his tenure, and for establishing the early infrastructure for the Finance organization. In my new role, I look forward to continuing to help shape the future of Bicara—both on the Board and supporting the leadership team as they build on this momentum and continue creating lasting value for patients, employees, and shareholders."

"On behalf of the Board, I want to thank Claire for her extraordinary vision, leadership, and commitment to building a company defined by scientific excellence, a deeply rooted culture, and an unwavering focus on patients. Throughout her tenure, Claire has led with a long-term perspective, and this leadership transition reflects her thoughtful stewardship and commitment to Bicara’s continued success," said Mike Powell, Chairman of the Board of Bicara Therapeutics. "The Board has great confidence in Ryan to lead Bicara into its next era of execution and growth. This transition also reflects the investments we have made to prepare for our next chapter—including strengthening our executive team with experienced commercial leaders, elevating outstanding internal talent, and expanding the Board with directors who bring deep operational and commercialization expertise. Together, these steps have created a management team equipped to execute on the significant opportunities ahead, position the company for its next stage of growth, and broaden Bicara’s impact for patients."

"It is an incredible privilege to lead Bicara at such an important moment in its journey. Since the early days of Bicara, I have had the opportunity to help shape our strategy, help build the organizational capabilities and leadership team at the appropriate time in the company’s evolution, and work alongside an extraordinary group of colleagues to bring the tremendous promise of ficerafusp alfa to many people around the world through our clinical trials," said Ryan Cohlhepp, President and COO. "I am deeply grateful to Claire for her partnership and unwavering commitment to the ongoing success of this organization, and to the Board for its confidence in me. As we look ahead, my focus will be on building on the exceptional foundation we have created together—establishing our commercial footprint, advancing a pipeline with discipline and purpose, and continuing to invest in the people and culture that make Bicara unique."

Leadership biographies may be accessed on the Bicara website.

Second Quarter 2026 Highlights and Recent Progress

Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC

Initiated FORTIFI-FLEX, a randomized, open-label, clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W). The company expects to have results from this study by the time of a potential U.S. accelerated approval in 1L R/M HPV-negative HNSCC.
Presented extended follow-up data out to three years from the Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negative HNSCC at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The data demonstrated deep, durable responses representing substantial improvements over standard of care treatment, observed to be driven by TGF-β inhibition, allowing for direct tumor penetration. Specifically, three-year follow-up from the 1500mg QW dose cohort showed an estimated OS rate of 31%, approximately doubling the survival rate observed in retrospective analysis with standard of care pembrolizumab in HPV-negative patients.
Key Anticipated Upcoming Milestones

HNSCC

Continued to enroll Phase 3 of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC and expect to be substantially enrolled by the end of the year to enable topline results from an interim analysis in mid-2027.
Other Solid Tumors, Including mCRC

Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in the second half of 2026.
Second Quarter 2026 Financial Results

Cash, Cash Equivalents and Marketable Securities: As of June 30, 2026, Bicara had cash, cash equivalents and marketable securities of $497.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.
Research and Development Expenses: Research and development expenses were $45.8 million for the second quarter of 2026 as compared to $24.8 million for the second quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, as well as the company’s ongoing Phase 1/1b dose expansion cohorts, and an increase in personnel costs.
General and Administrative Expenses: General and administrative expenses were $14.2 million for the second quarter of 2026 as compared to $7.2 million for the second quarter of 2025. The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as we advance in a pivotal study and prepare for potential commercialization.
Net Loss: Net loss totaled $55.4 million for the second quarter of 2026 compared to $27.4 million for the second quarter of 2025.
Upcoming Investor Conference

Bicara Therapeutics will participate in one upcoming investor conference:

2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 9:10 a.m. ET.
A live webcast of the fireside chat will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available for 30 days following the event.

Conference Call Information

Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss second quarter 2026 financial results and business updates, including strategic leadership transitions. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.

(Press release, Bicara Therapeutics, AUG 11, 2026, View Source [SID1234669977])

On August 11, 2026 Gibson Oncology, a clinical-stage oncology company developing blood-brain-barrier-penetrant therapies for brain tumors and other difficult-to-treat cancers, reported that the first patient in the Phase II clinical trial of LMP744 has been enrolled and has completed the initial treatment cycle without complication. The trial is being conducted by investigators at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and is evaluating LMP744 as a single agent in patients with recurrent glioblastoma (GBM). Gibson Oncology is providing partial funding and LMP744 to the trial under a Clinical Cooperative Research and Development Agreement (CRADA) with NINDS.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LMP744 is a novel, dual-acting anticancer agent that works by reducing overexpression of the cMyc oncogene and by inhibiting topoisomerase 1 (TOPO1), two validated targets across a range of solid and hematological cancers.

Glioblastoma is the most common and aggressive primary brain tumor in adults. Approximately 13,000 new cases are diagnosed in the United States each year, median survival is generally 15 to 18 months, and the five-year survival rate is under 10 percent. Recurrent glioblastoma, for which there is no established standard of care, carries an especially poor prognosis.

In preclinical studies, LMP744 crossed the blood-brain barrier and achieved brain concentrations approximately 10 times the level needed to kill cancer cells, with a half-life in the brain exceeding 24 hours for each dose. Blood-brain-barrier penetration has long been one of the central obstacles in the treatment of brain tumors.

The Phase II trial is designed to enroll a total of 40 first-time recurrent GBM patients with a Karnofsky Performance Status (KPS) of 60 or better, with a primary endpoint of progression-free survival and a secondary endpoint of overall survival. LMP744 is being studied as a single therapeutic agent based on the strong anticancer effects observed in GBM patient-derived xenograft (PDX) animal models.

LMP744 has previously completed one Phase I clinical trial with 36 patients in heavily pretreated cancer patients, many of whom had failed as many as eight prior individual or combination treatments. Over 30% of the patients on single agent treatment with LMP744 experienced stable disease for up to 30 months and 2 patients were partial responders, even as many patients were sub-optimally dosed to establish the drug’s safety and tolerability before reaching the therapeutic dose level of 190 mg/m2.

"Completing the first treatment cycle in this trial is an important early milestone for LMP744 and, most of all, for the patients who face recurrent glioblastoma with limited therapeutic options, and one of the most difficult cancers in medicine," said Randall Riggs, President and Chief Executive Officer of Gibson Oncology. "We are grateful to the clinical team at NINDS and to the patients and families taking part in this study, and we look forward to advancing LMP744 as a potential breakthrough treatment in an area that has experienced little improvement in treatment options for decades."

Mr. Riggs continued, "The renewed excitement about LMP744 is two-fold. First, LMP744 was found to migrate rapidly into the brain at high concentrations, well beyond the levels needed to kill cancer, with each dose having a half-life of over 24 hours. Second, in PDX animal models implanted with patient-derived recurrent gliomas, just five doses of LMP744 produced tumor eradication. Together, these findings made a compelling case for initiating this Phase II study at the NINDS."

About LMP744

LMP744 is a novel, dual-acting indenoisoquinoline that reduces cMyc overexpression and inhibits topoisomerase 1 (TOPO1). In preclinical studies, it has demonstrated blood-brain-barrier penetration and sustained brain exposure. LMP744 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for all gliomas, including DIPG.

(Press release, Gibson Oncology, AUG 11, 2026, https://www.globenewswire.com/news-release/2026/08/11/3342662/0/en/gibson-oncology-announces-first-patient-completes-initial-treatment-cycle-in-phase-ii-trial-of-lmp744-for-recurrent-glioblastoma.html [SID1234669976])

On August 11, 2026 SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, reported the publication of a peer-reviewed article in Biomedicines. Co-authored by SL Science leadership and clinical researchers from Taipei Medical University, the article outlines a rigorous development framework for γδ T cell therapy in glioblastoma –a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required to rigorously evaluate γδ T cell therapies in future human trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Strategic Impact on SL Science’s Business and Research

The publication serves as an industry roadmap while validating SL Science’s overarching business strategy and research direction. Glioblastoma remains notoriously difficult to treat because tumors rapidly mutate and evade traditional therapies aimed at a single target. In contrast, γδ T cells recognize cancer through universal stress signals rather than single antigens, target the stem-like cells responsible for tumor recurrence, and carry a low risk of graft-versus-host disease. This unique biology makes them suited for allogeneic, "off-the-shelf" manufacturing from healthy donors and repeated localized delivery directly to the brain, which is a model that directly mirrors SL Science’s FDA Drug Master File-backed platform. By publishing this framework alongside clinical researchers, SL Science establishes a clear standard of evidence for its own pipeline, supporting the design of future clinical programs to evaluate whether cells successfully reach, persist, and function within the tumor.

Translating Lab Science into Clinical Reality

To bridge the gap between promising laboratory data and actual patient outcomes, the framework outlines key operational shifts for clinical research. The authors stress that early-phase trials must embed quantitative cell-tracking and serial pharmacodynamic sampling to determine whether a treatment outcome is driven by cellular delivery, persistence, or functional exhaustion. Furthermore, cellular potency must be tested under realistic, low-oxygen and low-glucose tumor conditions rather than ideal laboratory environments. The article also supports direct, repeated delivery to the tumor cavity as a practical method to overcome the blood-brain barrier, while cautioning that trial endpoints should focus on verifiable biological activity before attempting to prove overall survival benefits in small, early-stage cohorts.

Management Commentary

"Glioblastoma has repeatedly defeated therapies that looked convincing in preclinical models. The clear lesson is that progress depends on rigorous evidence generation in humans, not further laboratory speculation," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "This publication defines what we believe the next phase of development must look like: clinical trials designed from day one to show whether these cells reach the tumor, remain viable, and execute their therapeutic function. Translating this science into actionable clinical proof is our core focus, and our technology is advancing and evolving alongside new clinical discoveries. We intend our own programs to meet the exact standard we have set out here."

Clinical Context and Regulatory Disclosures

The article maintains a transparent assessment of current clinical evidence, noting that γδ T cell therapy in glioblastoma remains investigational. The publication represents an independent narrative review co-authored by company leadership in their personal scientific capacities; it received no external funding, was conducted independently of any commercial product, and does not evaluate or endorse any specific proprietary SL Science candidate.

(Press release, SL Science, AUG 11, 2026, View Source [SID1234669975])

On August 11, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of August 7, 2026, TIGeR-PaC trial investigators have been notified by RenovoRx that patient enrollment is closing. Completion of the trial is expected during the first half of 2027, after 86 events (i.e., patient deaths) have been observed. As of August 11, 2026, 78 events have occurred. Following completion of the trial, initial top line trial data is expected to be available during the second half of 2027.

This significant milestone reflects successful patient recruitment, clinical execution, and collaboration among investigators and study teams evaluating intra-arterial gemcitabine (IAG) via RenovoCath delivered through RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) platform as a novel drug-device product candidate for difficult-to-treat LAPC. The primary endpoint of the study is overall survival. TIGeR-PaC is designed to evaluate whether RenovoRx’s patented method of targeted delivery of the chemotherapy gemcitabine improves patient survival, safety, and tolerability compared to the standard of care (systemic (intravenous) chemotherapy gemcitabine + Abraxane).

Pancreatic cancer continues to represent a major unmet medical need, with limited treatment options and current standards of care centered largely on systemic chemotherapy, which can cause significant toxicity and related side effects for patients. TAMP is designed to deliver chemotherapy directly near the tumor site while potentially reducing systemic exposure.

"The TIGeR-PaC Phase III study represents an exciting step forward in the treatment of LAPC," said Hassan Hatoum, MD Associate Professor of Medicine Medical Director, GI Oncology Disease Site Chair, GI Oncology Disease Site Group Stephenson Cancer Center University of Oklahoma Health Sciences Center and principal investigator at the University of Oklahoma Health for the TIGeR-PaC trial. "For far too long, patients with LAPC have had limited options beyond systemic chemotherapy. This novel treatment approach offers hope by adding an innovative, locoregional and targeted intervention that has the potential to improve outcomes beyond the current standard of care. The preliminary results of this study have been encouraging and reinforce the importance of continuing to explore new strategies for this challenging disease."

Dr. Hatoum continued, "What makes this approach particularly promising is its adaptability. Because the FDA-approved RenovoCath device administers chemotherapy directly near the tumor, it can continue to be integrated with a systemic therapy protocol regardless of how standard systemic treatment evolves in the future, this provides a versatile platform that can remain relevant as new chemotherapy regimens and targeted therapies emerge."

"I am proud to be part of the Phase III trial evaluating IAG, working alongside an exceptional multidisciplinary team committed to advancing care for patients with LAPC. Together, we are developing innovative treatment strategies that have the potential to improve outcomes and quality of life for our patients. Beyond pancreatic cancer, this novel platform also offers hope for expanding targeted regional chemotherapy delivery to other cancers, potentially opening new therapeutic opportunities across multiple solid tumors," concluded Dr. Hatoum.

"Completing enrollment in the Phase III TIGeR-PaC trial marks a major milestone for RenovoRx," said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. "TIGeR-PaC is the cornerstone of our clinical development program, and we are now closer than ever in our efforts to validate IAG and its efficacy through rigorous, long-term evaluation. We thank the participating clinical sites, the patients and their families for their dedication, support, and trust in this important study. With enrollment complete, we are now focused on advancing toward completion and data analysis. We believe TIGeR-PaC will provide meaningful additional validation of our TAMP therapy platform in an area with significant unmet need and limited therapeutic progress. The validation of this approach both in terms of tolerability and efficacy should provide additional tools for clinicians to offer patients in this challenging disease."

The study’s enrollment was supported by participation from nationally recognized cancer centers and academic medical institutions across the United States, including Johns Hopkins Medicine, University of Pittsburgh Medical Center, UT Southwestern Medical Center, University of Nebraska Medical Center, Baptist Health South Florida, Stephenson Cancer Center at the University of Oklahoma, and more.

The study has also progressed through two independent interim analyses triggered following the 26th event in 2023 and the 52nd event in 2025, with the study’s independent Data Monitoring Committee (DMC) recommending continuation of the trial on both occasions. Together, these accomplishments reflect the successful execution of RenovoRx’s lead clinical program and support continued evaluation of its proprietary TAMP therapy platform.

About RenovoCath
Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). RenovoRx’s first investigational drug-device combination product candidate, using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath device, is designed for the intra-arterial administration of chemotherapy, gemcitabine (IAG).

(Press release, Renovorx, AUG 11, 2026, View Source [SID1234669974])

On August 11, 2026 BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BBOT’s portfolio of RAS-pathway inhibitors is designed to enable direct dual inhibition of KRASG12C (BBO-8520), or KRASG12D/V (BBO-11818) in both its ON and OFF states as well as disruption of RAS-driven PI3Kα activation (BBO-10203) to achieve optimal target coverage of the most mutated driver oncogene in human cancer. Together, these assets uniquely position BBOT to achieve concurrent, high-level suppression of both the MAPK and PI3Kα pathways through a wholly-owned internal combination strategy.

"During the second quarter, we made meaningful progress in patient enrollment in our monotherapy and combination cohorts across each of our three clinical programs. Differentiated patient benefit in oncology is driven by optimal target coverage and the ability to combine with standard-of-care regimens. Therefore, we continue to focus heavily on advancing our combination development strategies," said Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT. "In addition, our wholly-owned portfolio is uniquely positioned to enable concurrent suppression of the MAPK and PI3Kα pathways through internal combination strategies of each of our KRAS inhibitors with BBO-10203. We are excited to have both combinations already underway in patients. With multiple near-term clinical milestones across all programs expected in the second half of 2026 and cash runway into 2028, we believe we are well positioned to execute our strategy and expand treatment options for patients with mutant KRAS-driven cancers."

Key Program Highlights and Updates

BBO-8520: An orally bioavailable small molecule direct inhibitor targeting both the ON and OFF states of KRASG12C.

Continued to enroll BBO-8520 plus pembrolizumab combination in patients with NSCLC carrying KRASG12C mutation.
Initiated BBO-8520 plus BBO-10203 combination in patients with G12C NSCLC.

BBO-11818: An orally bioavailable small molecule pan-KRAS inhibitor that targets mutant KRAS in both the ON and OFF states.

Continued to enroll BBO-11818 monotherapy across multiple dose levels.
Initiated dosing of BBO-11818 in combination with cetuximab.
Subsequent to the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203.
Presented preclinical data at AACR (Free AACR Whitepaper) highlighting the potency of BBO-11818 in KRASG12D and KRASG12V CDX models, potent combination effect with cetuximab or BBO-10203, and complete tumor regressions through adaptive immunity in combination with anti PD-1 antibodies.

BBO-10203: An orally bioavailable small molecule with a novel mechanism of action designed to block the physical interaction between RAS and PI3Kα, inhibiting RAS-driven PI3Kα-AKT signaling in tumors.

Continued to enroll HR+ BC, HER2+/HR- BC, and colorectal (CRC) combination cohorts.
Presented preclinical data at AACR (Free AACR Whitepaper) showing that BBO-10203 demonstrated strong in vivo combination effect with HER2 inhibitors tucatinib or trastuzumab in HER2amp tumor models.

Second Quarter 2026 Financial Results

Cash Position: As of June 30, 2026, BBOT had cash, cash equivalents and marketable securities totaling $344.1 million, which is expected to provide cash runway into 2028.
Research and development (R&D) expenses: R&D expenses were $49.2 million for the second quarter of 2026 compared to $27.4 million for the second quarter of 2025. The increase in expenses was primarily due to increases in clinical trial expenses and manufacturing expenses for BBO-8520, BBO-11818, and BBO-10203.
General and administrative (G&A) expenses: G&A expenses were $11.0 million for the second quarter of 2026 compared to $2.7 million for the second quarter of 2025. The increase in G&A expenses reflects the initiation of BBOT’s standalone operations, de-SPAC transaction, and one-time severance costs for former executives.
Net Loss: Net loss was $56.5 million for the second quarter of 2026 compared to $28.4 million for the second quarter of 2025.

(Press release, BridgeBio Oncology Therapeutics, AUG 11, 2026, View Source [SID1234669973])